# Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

Study · id `cardio:ct-nct05920889` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05920889](<https://clinicaltrials.gov/study/NCT05920889>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05920889

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

## Technical summary

Registry record NCT05920889. Randomized; no masking; primary purpose treatment. Start 2023-08-01 (actual); primary completion 2024-10-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 140 participants (enrolled count; ClinicalTrials.gov record NCT05920889, source copy `cardio:ctgov-nct05920889-2025-03-07`, retrieved 2026-10-26)
- Started: 2023-08-01 (actual) (ClinicalTrials.gov record NCT05920889, source copy `cardio:ctgov-nct05920889-2025-03-07`, retrieved 2026-10-26)
- Primary completion: 2024-10-25 (actual) (ClinicalTrials.gov record NCT05920889, source copy `cardio:ctgov-nct05920889-2025-03-07`, retrieved 2026-10-26)
- Completion: 2024-10-25 (actual) (ClinicalTrials.gov record NCT05920889, source copy `cardio:ctgov-nct05920889-2025-03-07`, retrieved 2026-10-26)
- Countries: China; Hong Kong SAR China (ClinicalTrials.gov record NCT05920889, source copy `cardio:ctgov-nct05920889-2025-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05920889-2025-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
- Acronym: GALLOP
- Condition: Stroke
- Condition: Stroke, Acute
- Condition: Stroke, Ischemic
- Condition: Brain Diseases
- Intervention (Drug): Semaglutide
- Lead sponsor: Chinese University of Hong Kong
- Lead sponsor class: OTHER
- Collaborator: Linyi People's Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Chinese University of Hong Kong (`cardio:org-chinese-university-of-hong-kong`)
- Registry lists this organization as a collaborator: Linyi People's Hospital (`cardio:org-linyi-people-s-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial (`cardio:pubmed-41392086`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a1b44c1cf300841fbe973701f809187092d9fdca139e9c42aea03da615cc3788
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
